Search results
American healthcare biotech venture capitalist
- Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. She focuses on investing in healthcare companies and early-stage biotech start-ups. She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY) and ByHeart, and represents Polaris as a director for Kallyope, Thirty Madison, QurAlis, and Larkspur.
en.wikipedia.org/wiki/Amy_Schulman
People also ask
Who is Amy Schulman?
How many jobs does Amy Schulman have?
Who is Amy Schultz?
Who is Emily Schuman?
Did Amy Schulman make mistakes?
Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. [1] [2] [3] She focuses on investing in healthcare companies and early-stage biotech start-ups.
Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. [1] [2] [3] She focuses on investing in healthcare companies and early-stage biotech start-ups.
Amy Schulman. Amy is a managing partner at Polaris Partners who focuses on investing in healthcare companies and early stage biotech start-ups. She serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and as chair of the Board of Directors of ByHeart.
Jan 1, 2014 · Amy Schulman is the Chief Executive Officer at Arsia Therapeutics since August 2014. Arsia, a biotechnology company focused on improving patients’ lives through new modes of drug delivery, and a venture partner at Polaris, a leading venture capital firm with approximately 4 billion under management in August of 2014. Amy joined Polaris.
- Female
- Lyndra Therapeutics
Jul 29, 2014 · Polaris Venture Partner Amy Schulman. Exactly one year ago, Amy Schulman was in line for a big promotion. Her company, Pfizer ($PFE), was preparing to split into three segments, and CEO Ian...
- Damian Garde
The current managing partners are Amy Schulman, and Brian Chee. [1] [8] Polaris Partners also has two affiliate funds. Polaris Growth Fund targets investments in profitable, founder-owned technology companies and is led by managing partners Bryce Youngren and Dan Lombard.
Nov 10, 2010 · Amy Schulman joined Pfizer two years ago as general counsel and led the legal team in the drug maker's $68 billion acquisition of Wyeth Pharmaceuticals in 2009. The National Law Journal named her ...
